Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | ESR1 | P03372 | 4/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028587 | 0.96 | TDP1 (1.00) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL2085135 | 0.96 | TDP1 (1.00) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Benzene SCHEMBL6890099 | 0.96 | TDP1 (1.00) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL101 | 0.96 | TDP1 (1.00) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL25384985 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL20582981 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL480830 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL22445084 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL22558063 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL11170638 | 0.92 | TDP1 (0.92) | TDP1CYP3A4ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | claimed |
| EP-2268638-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | claimed |
| US-20240148727-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11911381-B2 | Optically active azabicyclo ring derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11643418-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11369605-B2 | Optically active azabicyclo ring derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3689881-B1 | MACROCYCLIZATION REACTIONS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B | EISAI R&D MAN CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210338668-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3845533-A1 | OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-07-07 | — | — | EP | disclosed |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004108215-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-6790501-B2 | DATA LAYER; REFLECTIVE SILVER OR GOLD LAYER THAT IS OXIDATION RESISTANT; AND REACTIVE LAYER COMPRISING DYE HAVING REDUCED AND OXIDIZED STATES; SILVER OR GOLD. | GENERAL ELECTRIC COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040116690-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040022986-A1 | Limited-play optical media with improved shelf-life and playability | GENERAL ELECTRIC COMPANY | 2004-02-05 | — | — | US | disclosed |
| WO-2004010426-A2 | LIMITED-PLAY OPTICAL MEDIA WITH IMPROVED SHELF-LIFE AND PLAYABILITY | GENERAL ELETRIC COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | TDP1 4027/4885CYP3A4 3577/4885ESR1 4176/4885 |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | TDP1 2336/4885CYP3A4 803/4885ESR1 995/4885 |
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | PTGIR, PTGDR, PTGER1 | TDP1 4351/4885CYP3A4 1649/4885ESR1 1718/4885 |
| US-11369605-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | TDP1 3785/4885CYP3A4 2368/4885ESR1 1321/4885 |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | NR3C1, MC2R, FPR1 | TDP1 3045/4885CYP3A4 2281/4885ESR1 2628/4885 |
| US-11911381-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | TDP1 3803/4885CYP3A4 2484/4885ESR1 1435/4885 |
| US-11643418-B2 | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B | ERLIN1, MAN1B1, DHPS | TDP1 3608/4885CYP3A4 1735/4885ESR1 1555/4885 |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | MLLT3, MLLT1, MEN1 | TDP1 4381/4885CYP3A4 3235/4885ESR1 1228/4885 |
| US-20240148727-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | MLLT3, MEN1, MLLT1 | TDP1 3803/4885CYP3A4 2484/4885ESR1 1435/4885 |
| US-20210338668-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | MLLT3, MEN1, MLLT1 | TDP1 3785/4885CYP3A4 2368/4885ESR1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.